How Tumors Build Their Own Blood Supply

How Tumors Build Their Own Blood Supply?

If you or a loved one has been diagnosed with cancer, you may have heard the term "angiogenesis" in a doctor's office or read it on a pathology report. It sounds complex, but it’s a concept that is central to understanding how cancer grows—and how we can stop it. This is the story of how a tumor builds its own lifeline, and what that means for your treatment journey.

What Is Angiogenesis?

Angiogenesis is the process your body uses to build new blood vessels. Under normal, healthy circumstances, this is a good thing. It helps heal wounds, repair muscles, and support growing tissues. Your body tightly controls this process, turning it on only when needed and off when the job is done.

But cancer hijacks this system. A tumor is a growing mass of cells, and like any living tissue, it needs oxygen and nutrients to survive. To keep growing beyond a tiny size (about the tip of a ballpoint pen), a tumor must create its own blood supply. It does this by sending out signals that trick your body into building new blood vessels directly into the tumor. This process—abnormal, uncontrolled blood vessel growth directed by a cancer—is called tumor angiogenesis.

How a Tumor "Flips the Switch"

Think of angiogenesis like a construction project. Your body has genes that act as "architects" who draw up plans for new blood vessels. It also has genes that act as "safety inspectors" who make sure no unnecessary building happens.

Two of the most important players are:

• VEGF (Vascular Endothelial Growth Factor): This is the primary "GO" signal. It’s a protein that tells the body, "We need new blood vessels here, now!"
• TP53 (often called the ‘guardian of the genome’): This is a major "STOP" signal. This gene’s job is to prevent faulty construction. It ensures cells don’t grow out of control.

In many cancers, a mutation occurs that breaks the TP53 "inspector." At the same time, the tumor starts overproducing massive amounts of the VEGF "GO" signal. It’s like a corrupt foreman firing the safety inspector and then constantly blaring the alarm to build, build, build. This results in a rush job: a messy, leaky, and inefficient network of blood vessels that exists only to feed the tumor.

Why This Hallmark Matters in Cancer

This process is not a side effect; it is a fundamental hallmark of cancer. Without angiogenesis, a tumor simply cannot grow large or spread to other parts of the body (a process called metastasis). Those new blood vessels act as highways for cancer cells to enter the bloodstream and travel elsewhere.

VEGF signaling is particularly crucial. Mutations or overactivity in the VEGF pathway are found in a vast majority of solid tumors, including:

• Colorectal cancer (up to 50% of cases)
• Non-small cell lung cancer
• Renal cell carcinoma (kidney cancer)
• Glioblastoma (a type of brain tumor)
• Many breast, ovarian, and prostate cancers

This makes the angiogenesis process a powerful and common target for treatment.

What It Means for Treatment: Starving the Tumor

For decades, the main strategy against cancer was to directly kill cancer cells with chemotherapy or radiation. The discovery of angiogenesis led to a brilliant new strategy: instead of attacking the tumor itself, attack its supply lines. If you can stop the construction of new blood vessels, you can starve the tumor.

This class of drugs is called angiogenesis inhibitors or antiangiogenic therapy. They are essentially "VEGF blockers." They work by mopping up the extra VEGF "GO" signals or by blocking the docks (receptors) where those signals land on blood vessel cells.

You might know some of these drugs by name:

• Bevacizumab (Avastin®): Used for colorectal, lung, kidney, brain, and cervical cancers.
• Sunitinib (Sutent®) & Pazopanib (Votrient®): Used for kidney cancer and certain soft tissue sarcomas.
• Aflibercept (Zaltrap®): Used for metastatic colorectal cancer.

These drugs are often combined with chemotherapy to deliver a one-two punch: cut off the supply lines and then attack the weakened tumor.

What You Can Do: Knowledge and Questions

Understanding angiogenesis empowers you to be a more active participant in your care. If your cancer type is one where angiogenesis plays a key role, here’s how you can use this knowledge:

1. Ask Your Oncologist: In your next appointment, you can ask, "Is angiogenesis important in my type of cancer?" and "Are antiangiogenic drugs like VEGF inhibitors a potential part of my treatment plan?"
2. Understand the Goal: These treatments are often used to control cancer growth and manage it as a chronic condition, even if they don't always provide a outright cure. Knowing this helps set realistic expectations.
3. Look into Clinical Trials: Research into newer, more precise angiogenesis inhibitors is ongoing. Ask your care team if there are any clinical trials for which you might be eligible.

The fight against cancer is fought on many fronts. By understanding how a tumor builds its own blood supply, we found a critical weakness. Today, treatments that target this process are helping thousands of people around the world live longer, fuller lives with cancer.